Number of lines of previous chemotherapy regimen might affect the oucome of sacituzumab govitecan in metastatic triple-negative breast cancer patients
Breast Cancer · 2024
DOI: 10.1007/s12282-024-01587-1 ↗Kurz gefasst
Leserbrief in der Zeitschrift Breast Cancer, 2024. Verfasst von Kadri Altundag. Beteiligte Einrichtung: Tepe Prime, MKA Breast Cancer Clinic, Cankaya, 06800, Ankara, Turkey. altundag66@yahoo.com. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Camptothecin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 2 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Tepe Prime, MKA Breast Cancer Clinic, Cankaya, 06800, Ankara, Turkey. altundag66@yahoo.com.
Zitieren
APA
Altundag, K. (2024). Number of lines of previous chemotherapy regimen might affect the oucome of sacituzumab govitecan in metastatic triple-negative breast cancer patients. Breast Cancer. https://doi.org/10.1007/s12282-024-01587-1
Vancouver
Altundag K. Number of lines of previous chemotherapy regimen might affect the oucome of sacituzumab govitecan in metastatic triple-negative breast cancer patients. Breast Cancer. 2024. doi:10.1007/s12282-024-01587-1
BibTeX
@article{Altundag2024,
author = {Altundag, Kadri},
title = {Number of lines of previous chemotherapy regimen might affect the oucome of sacituzumab govitecan in metastatic triple-negative breast cancer patients},
journal = {Breast Cancer},
year = {2024},
doi = {10.1007/s12282-024-01587-1}
}
EUVIMED